Kornimate/medical-research-clean huggingface dataset:
the effectiveness of single antibiotic paste nitrofurantoin versus double antibiotic paste

Conditions: Pain; Symptomatic Irreversible Pulpitis

Summary: in our study, we used nitrofurantoin as a root canal medication in patients suffering from symptomatic irreversible pulpitis in alleviating pain compared with double antibiotic paste.

this study aims to compare the efficacy in alleviating pain between intracanal medicaments nitrofurantoin versus double antibiotic paste.

Eligibility criteria:
inclusion criteria: * no medical history * no history of allergy to medications used in root canal treatment * patients suffering from symptomatic irreversible pulpitis exclusion criteria: * patients who were not suitable for conventional root canal treatment * multirooted teeth
high vs low-frequency of high-intensity training in chronic stroke

Conditions: Stroke

Summary: the purpose of this pilot study is to investigate the potential role of training frequency on locomotor outcomes following high-intensity gait training and provision of a home walking program.

this study will utilize a 2 arm randomized trial to investigate potential differences in locomotor and community outcomes following 18 visits of high-intensity gait training provided over 6 weeks (high frequency) or 12 weeks (low frequency). following confirmation of eligibility and baseline testing, individuals will be randomized to either high or low frequency of training and complete subsequent testing at 6 weeks, 12 weeks, and 24 weeks.

Eligibility criteria:
inclusion criteria: * unilateral deficits following stroke \&gt; 6 months prior; however individuals \&gt; 4 months post-stroke are eligible for consenting, but final eligibility and potential enrollment will not occur until \&gt; 6 months * age 18-85 * weight \&lt; 350 pounds * able to follow 3-step commands * able to ambulate with self-selected gait speeds between 0.10-1.0 m/s without physical assistance, but with below knee bracing and/or assistive device as needed * lower extremity fugl-meyer \&lt; 34 * medical clearance to participate exclusion criteria: * evidence of cerebellar ataxia * uncontrolled cardiopulmonary or metabolic disease that limits exercise participation, active heterotopic ossification, recurrent history of lower extremity fractures, previous orthopedic or other peripheral or central neurologic injury that may impair locomotor activities such that, in the judgement of the pi, could compromise the safety of the participant, limit the ability to complete the study, or compromise the objectives of the study. * currently participating in other physical therapy * \&gt;50 units of botox in the lower extremity or in the lower extremity, but above the knee if the participant wears an ankle-foot-orthosis (afo) within the past three months

Keywords: stroke gait rehabilitation high-intensity frequency
fibtem predicts postoperative bleeding

Conditions: Postoperative Hemorrhage

Summary: retrospective study to evaluate if fibtem predicts the amount of postoperative bleeding in total knee replacement patients.

this retrospective study evaluate patients who underwent total knee replacement arthroplasty. laboratory coagulation parameters, including fibtem, before anesthesia induction and after admission to the post-anesthetic care unit and decrement of postoperative haemoglobin and amount of transfusion were reviewed. a correlation coefficient of ρ = 0.4 was calculated from a pilot study. we need at least 44 subjects with an α value of 0.05 and a power of 0.8.

Eligibility criteria:
inclusion criteria: * patients who underwent primany unilateral total knee replacement arthroplasty under general anesthesia * patients who had fibtem performed exclusion criteria: * surgery under regional anaesthesia * a simultaneous bilateral total knee replacement arthroplasty * the second surgery of staged total knee replacement arthroplasty * revision of total knee replacement arthroplasty * patients who received intraoperative transfusion * patients who use tranexamic acid * patients who received fibrinolytic agents because of perioperative thromboembolic event * patients who refused transfusion because of religious belief of personal causes

Keywords: fibtem total knee replacement
early neurological clinical recovery, 3 months after endovascular treatment of an acute ischemic stroke

Conditions: Stroke, Acute

Summary: this trial aims at collecting standardized data concerning the early neurological clinical recovery of patients, 3 months after endovascular treatment of an acute ischemic stroke. although this outcome is a major issue of patients' prognosis, it is rarely collected at this stage of their follow-up.

stroke affects 1 patient every 4 minutes in france, with around 130,000 new patients each year. early recanalisation is a major prognostic factor and the main therapeutic target in the acute phase of this disease. the recanalisation techniques currently developed are intravenous thrombolysis, intra-arterial thrombolysis and thrombectomy (or embolectomy). these therapies can be combined. thrombectomy involves endovascular capture of the clot obstructing the intracranial artery. recent improvements in thrombectomy techniques have also contributed to the spread of this technique. neurovascular units include endovascular treatment in their strategy for the early management of acute proximal occlusions of intracranial arteries in almost 1 in 3 cases. this approach is currently the subject of professional agreements. mechanical thrombectomy has now been validated by studies showing a major reduction (-35%) in the disability associated with severe cerebral infarction and a reduction in mortality, with recanalisation rates ranging from 58 to 72%. this "recanalisation" criterion is of major importance because it largely determines the functional prognosis of patients following a cerebral infarction. patients are often followed up in the months following the operation by the neurology department that initially treated them, and in the first few weeks they may be admitted to follow-up care units. as a result, although the clinical outcome at 3 months is a major factor in patient prognosis, this information is rarely available. the aim of this study is to obtain standardised 3-month follow-up data for a large series of patients who have undergone endovascular treatment for stroke.

Eligibility criteria:
inclusion criteria: * acute ischemic stroke * endovascular treatment exclusion criteria: * none
a study for the identification of biomarker signatures for diagnosis of pulmonary hypertension (ph) in participants at low or intermediate probability of ph undergoing cardiac magnetic resonance imaging

Conditions: Hypertension, Pulmonary

Summary: the primary purpose of this study is to estimate the percentage of participants in the population considered clinically as not having pulmonary hypertension (ph) that are positive for ph biomarker (micro ribonucleic acid \[rna\]); estimate the percentage of participants in the population considered clinically as not having ph that are positive for ph by cardiac magnetic resonance imaging (mri) and compare results of the mri to the biomarker results; to determine the performance of the biomarker signatures identified in the cipher (napuh0001) study in terms of sensitivity, specificity, positive predictive value (ppv) and negative predictive value (npv), in a population considered clinically as not having ph.


Eligibility criteria:
inclusion criteria: * referred for diagnostic work-up for pulmonary hypertension (ph) * with low or intermediate (but not high) probability of ph by transthoracic echocardiography (tte) according to european society of cardiology (esc)/ european respiratory society (ers) guidelines if at the time of enrollment right heart catheterization (rhc) is not deemed to be clinically indicated * medically stable on the basis of physical examination, medical history and vital signs performed at screening. any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and initialed by the investigator * must sign an informed consent (icf) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study * must sign a separate approval in the icf if he or she agrees to provide an optional (dna) sample for research. refusal to give consent for the optional (dna) research sample does not exclude a participant from participation in the study exclusion criteria: * undergone rhc within 2 years * participants requiring renal dialysis * participants post-lung or heart transplant * severe left ventricular dysfunction: left ventricular ejection fraction less then (\<) 35 percent * ongoing contagious respiratory disease
effects of dienogest and dienogest plus estradiol valerate in ovarian endometrioma

Conditions: Ovarian Reserve

Summary: progesterone resistance in endometriosis is a known fact. the progestin derivatives used in endometriosis cause decidualization and atrophy of ectopic foci. moreover, they inhibit neo-angiogenesis, provide suppress expansile/destructive growth facilitated by matrix metalloproteinases, and implantation of ectopic foci. the effect of drugs containing the estrogen-progesterone combination is mainly based on the inhibition of ovulation, decidualization and atrophy of ectopic foci. in estrogen-progesterone mechanism, it is known that estrogen has a progesterone receptor-enhancing effect, which may make progesterone more potent. based on this, the investigators hypothesized that estrogen added to progesterone could lead to a further reduction in endometrioma size by various mechanisms which probably include the increased progesterone sensitivity in endometriosis. in addition, the investigators hypothesized that this therapy can alleviate the destructive effect of endometriomas on the ovarian reserve.


Eligibility criteria:
inclusion criteria: 1. study group: at least one endometrioma greater than 3 cm, between 18-40 years of age, without surgical indication at the time of diagnosis, occasionally and intermittently controlled pain with nsaids or no pain symptom 2. control group: patients with reproductive age without any ovarian cysts exclusion criteria: * suspicion of malignancy, irregular mentrual period, endocrine diseases, drug intake that may affect ovarian reserve in the last 6 months (i.e gnrh agonists), previous ovarian surgery, amh levels under 2 ng/ml.

Keywords: endometrioma estradiol valerate + dienogest dienogest ovarian reserve
characterization of vaccine-induced responses against monkeypox (movihvax) an observational prospective cohort study

Conditions: Monkeypox

Summary: this observational study has been designed to characterize humoral and cellular immune responses after vaccination against monkeypox (mkp) in hiv positive and negative individuals at high risk of mkp infection during the vaccination campaign in the current monkeypox outbreak.

of the 23,837 cases of monkeypox reported in the european region of the who, 7.037 have been identified in spain, according to the national epidemiological surveillance network (renave). most of diagnosed individuals are men born in spain, being nearly 40% hiv positive. the clinical evolution was satisfactory, although 3-7% of cases required hospitalization. given the limited number of available doses of the mva-bn vaccine, it has been recently approved its use as a single intradermal dose. however, this posology can be more reactogenic than subcutaneous injection and there is limited data on its immunogenicity and effectiveness in people living with hiv (plwh), which account for about half of the monkeypox cases in the current outbreak. the present observational study has been designed to investigate the humoral and cellular immune responses following monkeypox vaccination in plwh.

Eligibility criteria:
inclusion criteria: 1. adult individuals of ≥18 years old. 2. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the trial. 3. has understood the information provided and capable of giving informed consent. exclusion criteria: 1. participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.

Keywords: monkeypox vaccine immune responses hiv
radial optic neurotomy in central retinal vein occlusion : a randomized trial

Conditions: Retinal Vein Occlusion

Summary: natural evolution of severe central retinal vein occlusion with low visual acuity is very poor. a randomized clinical trial will compare troxerutin and platelet anti-aggregating agents (drug treatment) versus surgery and drug treatment. surgery will include vitrectomy and radial optic neurotomy. the primary outcome will be vision measured 6 months after surgery.

central retinal vein occlusion (crvo) is the second most frequently retinal vascular disease causing loss of vision, after diabetic retinopathy. no treatment of crvo has clearly demonstrated beneficial and long lasting visual results. commonly used treatment options are platelet anti-aggregating agents, correcting rheologic factors with troxerutin and isovolumic hemodilution. surgical treatment of crvo has recently been proposed (2001) and has been studied in numerous non comparative pilot studies. limited but encouraging results motivate our randomised controlled trial. we will evaluate at 6 months visual acuity after surgery associating pars plana vitrectomy and radial optic neurotomy, in patients with central vein occlusion and bad vision, associated with the correction of rheologic factors.

Eligibility criteria:
inclusion criteria: * central retinal vein occlusion oedematous or hemorrhagic (at fundus exam and at fluorescein angiography) * visual acuity (va) ≤ 20/200 with etdrs charts * decreased va since more than 1 month, less than 3 months * common care recommendations for crvo during the period before recruitment (control ocular pressure if associated hypertension or glaucoma ; hemodilution if hematocrit ≥ 38% ,if no cardio-vascular contra-indication, to maintain hematocrit under 38% during 6 weeks ; troxerutin (3 /d) and aspirin (100 - 160 mg/d) ; clinical and angiographic controls to look for retinal ischemia indicating laser prp to prevent neovascular glaucoma. * signed informed consent. exclusion criteria: * ischemic crvo : 1- more than 30 disc diameters of ischemia at fluorescein angiography and/or •2- if angiogram is uninterpretable because of hemorrhages, deficit of afferent pupillary reflex 0.9 with photographic filters (proposed by hayreh) with indication to do laser prp or laser prp already done, * rubeosis or neovascular glaucoma, * bilateral diabetic retinopathy preproliferative or proliferative, * uncharacterized coagulation disease, or anticoagulant treatment, * untreated systemic disease (diabetes, severe high blood pressure, cardiac failure) ou eye disease (glaucoma), * contra-indication or documented allergy to troxerutin or platelet anti-aggregating agents, * contra-indication to surgical procedure * incapacity to received an informed consent, incapacity to follow all the study schedule

Keywords: retinal vein occlusion vitrectomy surgery retinal disorders vascular diseases
perioperative vaping complications

Conditions: Vaping; Complication of Anesthesia

Summary: prospective observational study evaluating the incidence, and qualifying the types, of perioperative pulmonary complications in patients that vape.

the primary objective of our study is to determine the rate at which patients that vape or use e-cigarettes experience perioperative pulmonary complications during and following general anesthesia. complications of interest will include postoperative atelectasis with hypoxemia necessitating oxygen therapy, pneumothorax, pneumonia, bronchospasm, bronchospasm requiring bronchodilator therapy, exacerbation of underlying pulmonary disease, pneumonia, ards, and acute respiratory failure. hospital course, including prolonged pacu stay, prolonged hospital admission for inpatients, and rate of icu admissions, will also be investigated. a secondary objective will be to further investigate and include the relationship between vaping cessation timeline in the preoperative period and the occurrence of ppcs, which is similarly underreported in the literature. furthermore, the study will assess how effectively anesthesia providers are screening for vaping or e-cigarette use as part of the preoperative evaluation, given that "it is unclear whether anesthesiologists and surgeons routinely ask patients explicitly about vaping" in the pre-operative setting. this lack of representative screening for vaping further obscures an understanding of the relationship between vaping, vaping cessation, and ppcs.

Eligibility criteria:
inclusion criteria: * surgical patient * general anesthesia * hx of vaping * age ≥12 exclusion criteria: * age \<12 * pregnancy * active preoperative pulmonary infection * recent pulmonary infection (within 8 weeks) * active tobacco smoker * poorly controlled reactive airway disease (requires more than prn albuterol) * non-lung protective ventilation

Keywords: vaping hypoxemia bronchospasm perioperative pneumonitis
drug-eluting bead, irinotecan therapy for unresectable intrahepatic cholangiocarcinoma w/concomitant gemcitabine and cisplatin or carboplatin

Conditions: Unresectable Intrahepatic Cholangiocarcinoma

Summary: the purpose of this study is to find out if the combination of trans-arterial chemoembolization (lc or oncozene bead) plus infusional chemotherapy is safe and more effective than just receiving the infusional chemotherapy alone.


Eligibility criteria:
inclusion: * patients over 18 years of age, of any race or sex, who have histologic and radiologic evidence of intrahepatic cholangiocarcinoma, who have been deemed unresectable by an experienced hepatic surgeon, and who are able to give informed consent, will be eligible * patients with at least one measurable liver tumor, with size \> 1cm (modified recist criteria) * patients with liver-dominant disease defined as ≥80% tumor burden confined to the liver * non-pregnant with an acceptable contraception in premenopausal women. * hematologic function: anc ≥ 1.5 x 109/l, platelets ≥ 75 x109/l, inr ≤1.3 (patients on therapeutic anticoagulants are not eligible if they can not stop there anti-coagulation prior to debiri and meet inr criteria) * adequate liver function as measured by: total bilirubin ≤ 2.0 mg/dl, * adequate renal function (creatinine ≤ 2.3 mg/dl) * women of child bearing potential and fertile men are required to use effective contraception (negative serum βhcg for women of child-bearing age) * signed, written informed consent * less than 70% of liver parenchymal tumor replacement exclusion: * patient eligible for curative treatment (i.e. resection or tumor ablation). * active bacterial, viral or fungal infection within 72 hours of study entry * women who are pregnant or breast feeding * ecog performance status score of \>3 * life expectancy of \< 3 months * allergy to contrast media that cannot be managed with standard care (e.g. steroids), making magnetic resonance imaging (mri) or computed tomography (ct) contraindicated * presence of another malignancy with the exception of cervical carcinoma in situ and stage i basal or squamous cell carcinoma of the skin. * any contraindication for hepatic embolization procedures: * large shunt as determined by the investigator (pretesting with tcmma not required) * severe atheromatosis vascular disease that precludes arterial cannulization * hepatofugal blood flow * main portal vein occlusion (e.g. thrombus or tumor) * other significant medical or surgical condition, or any medication or treatment, that would place the patient at undue risk and that would preclude the safe use of chemoembolization or would interfere with study participation * patients with prior contraindications for the use of irinotecan, gemcitabine, or cisplatin * patients who have received prior systemic therapy with either irinotecan, gemcitabine, or cisplatin

Keywords: lc bead irinotecan oncozene bead
lymphedema prevention in breast cancer

Conditions: BREAST CANCER; LYMPHEDEMA

Summary: objective: to find out the effectiveness of early application of physical therapy in the prevention of lymphedema after breast surgery and lymphadenectomy. design: randomized, controlled and single blinded clinical trial. three years duration. patients will be randomly assigned to one of these groups: experimental group: early physical therapy + training in means of prevention; control group: just training in means of prevention. in both groups several physical therapy assessments will be undertaken: 1st before surgery; 2nd immediately after surgery; 3rd after completing intervention; 4th, 5th and 6th after 3, 6, 12 and 24 months. subjects: women with breast cancer treated with breast surgery including lymphadenectomy in principe de asturias hospital, provided that there is no contraindication for physical therapy, and after reading, understanding and freely signing an informed consent form. sample size: a total of 116 subjects will be included in the study (58 subjects in each group), assuming a 15% of drop-outs and at least 20% reduction, with a statistical power of 60%. data analysis: to find out the effectiveness of intervention we will compare the rate of lymphedema in both groups by means of a logistic regression analysis, in which the main factor is the intervention group. other factors aimed to control the effect of the intervention will also be included. in order to compare the rate of appearance of lymphedema in both groups, a survival analysis will also be included.


Eligibility criteria:
inclusion criteria: * consecutive women diagnosed with breast cancer and undergoing unilateral surgery with axillary lymph-node dissection at the príncipe de asturias hospital in alcalá de henares, madrid (spain) are candidates for inclusion in the study. exclusion criteria: * patients without axillary lymph-node dissection or with bilateral bc, systemic disease, locoregional recurrence, or any contraindication to physical therapy are excluded from the study.

Keywords: lymphedema prevention breast cancer physical therapy
ratio of inferior vena cava and aorta diameter in dehydrated children

Conditions: Dehydration

Summary: * there is no definite tool for measurement of dehydration in children * subjective clinical dehydration scale is considered as valuable scoring system, but it cannot be reliable among clinicians sometimes. * some authors found inferior vena cava/aorta ratio can be a objective marker for dehydration * however, there is no evidence of correlation between clinical dehydration scale and inferior vena cava/aorta ratio * we will observe correlation between clinical dehydration scale and inferior vena cava/aorta ratio and change of the ratio according to hydration with intravenous normal saline infusion.


Eligibility criteria:
inclusion criteria: * all children with dehydration who visit emergency department exclusion criteria: * congenital heart disease * bronchopulmonary dysplasia * renal disease * liver disease